Further innovative early clinical trials (see https://dktk.dkfz.de/en/research/clinical-trials for an overview), performed within the Joint Funding Program and beyond, include peptide vaccination in patients with leukemia, breast cancer, and brain cancer (including academic GMP production of personalized peptide vaccines), the use and validation of demethylating substances as therapeutic agents across cancer entities, and diagnostic PSMA (prostate‐specific membrane antigen) radiopharmaceuticals for prostate carcinoma imaging. This evidence concerns the gene FOLH1 and prostate carcinoma.